Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy-Reference-Cited by-同舟云学术

Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy

Published:2022 Issue:7 Volume:13 Page:840-849
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Comert Onder Ferah¹²³^ORCID,Siyah Pinar⁴,Durdagi Serdar⁴,Ay Mehmet³,Ozpolat Bulent²⁵

Affiliation:

1. Department of Medical Biology, Çanakkale Onsekiz Mart University, Faculty of Medicine, 17020 Çanakkale, Turkey

2. Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 422, Houston, TX 77030, USA

3. Department of Chemistry, Natural Products and Drug Research Laboratory, Çanakkale Onsekiz Mart University, Faculty of Science and Arts, 17020 Çanakkale, Turkey

4. Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahcesehir University, 34734 Istanbul, Turkey

5. Center for RNA Interference and Non-Coding RNAs, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K) has been shown to be an important molecular driver of tumorigenesis and validated as a potential novel molecular target in various solid cancers including triple negative breast cancer (TNBC).

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D2MD00105E

Reference54 articles.

1. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation

2. Mechanism of elongation factor 2 (EF-2) inactivation upon phosphorylation Phosphorylated EF-2 is unable to catalyze translocation

3. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles

4. Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer

5. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A concise review on recent development of indole derivatives for anticancer activities;Journal of the Indian Chemical Society;2024-10

2. Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy;Drug Discovery Today;2024-10

3. Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors;ACS Omega;2024-09-10

4. Combination eEF2K gene and drug delivery for treatment of breast cancer;Journal of Bioactive and Compatible Polymers;2024-08-02

5. Precision Targeting Strategies in Cancer Therapy: Focusing on Synthetic Lethality with FAK Inhibition;2024-05-22